UI Investissement
VC Fund
Paris, France
UI Investissement is a VC fund in Paris focused on Manufacturing and Software. Since 1967, the UI brand embodies a partnership with companies. Actor of the economy, UI has accompanied more than 120 SMEs over the last fifteen years, investing more than 550m € and giving substance to their development projects. Combining experience and corporate culture, UI has established itself as an involved and independent partner, able tocount on its shareholder leaders to favor, independently, the sustainable performance of the SMEs it accompanies.
- Total investments:
- 107
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $37M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries UI Investissement invests in
Stages UI Investissement invests in
Countries UI Investissement invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $1.5M–$5.8M
- Series A
- $3.2M–$33M
- Private Equity
- $3.2M–$49M
Investment Focus
Industry
- Manufacturing 27 (25%)
- Software 14 (13%)
- Health Care 14 (13%)
- Biotechnology 10 (9%)
- Information Technology 10 (9%)
Stage
- Private Equity 31 (29%)
- Seed 20 (19%)
- Series A 19 (18%)
- Funding Round 15 (14%)
- Series B 6 (6%)
Country
- France 85 (79%)
- Spain 2 (2%)
- Canada 1 (1%)
- Belgium 1 (1%)
- Switzerland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hugues Béringer
Private Equity Associate
|
Private Equity Associate | Total investments: 1 | Find email | |
Michel Deprez
Managing Partner& Owner
|
Managing Partner& Owner | Total investments: 0 | Find email | |
Stéphanie Pépineau
Associate Director
|
Associate Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Brenus Pharma
|
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $12.6M / Series A / Jul 20, 2026 | |
Eclore
|
Eclore utilizes origami-inspired designs to produce cylindrical and flat protective bellows, as well as specific protection kits for SCARA robots. These components are constructed from materials resistant to solvents, oils, ultraviolet rays, and high-pressure cleaning while maintaining compliance with international standards. The products functionthrough compression and expansion cycles to safeguard equipment from environmental contaminants and mechanical wear. By reducing the total number of parts and overall bulk, the folding technology creates lightweight protective barriers suitable for various industrial diameters. | $3.6M / Seed / Feb 09, 2026 | |
Bobine Chemistry
|
Bobine is developing a chemical plastic recycling technology that enables the production of virgin-grade polymers from non-recyclable plastic waste. By utilizing heterogeneous catalysis and electromagnetic induction, this technology allows for the large-scale production of olefins from waste without the need for steam cracking or hydrotreatment. | $15.3M / Seed / Feb 04, 2026 | |
RUTILE.bike
|
Rutile. bike is a company specialising in reconditioned electric bikes, emphasising sustainability and quality. Customers benefit from a one-year warranty and repair support, including coverage for repair costs when serviced through their Lyon facility or partner workshops. The service includes personalized advice via videoconference or in physicalshowrooms located in Lyon and Paris, with bike pickup options available across ten French cities. Bikes are delivered within 72 hours, mostly pre-assembled for user convenience. Rutile aims to provide the best value electric bikes through a socially and environmentally responsible business model, promoting solidarity and sustainability in the cycle industry . | $2.3M / Seed / Nov 24, 2025 | |
Exeliom
|
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $3.3M / Series A / Oct 21, 2025 | |
Fungu'it
|
A new generation of flavor ingredients for healthy, sustainable, and accessible food. | $4.6M / Seed / Jun 17, 2025 | |
|
Fungu'it
|
A new generation of flavor ingredients for healthy, sustainable, and accessible food. | $4.6M / Seed / Jun 17, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Fizimed
|
Fizimed has made the choice to develop the EMY perineal probe with recognized health professionals. The probe is connected to a mobile app and associated with custom exercises. The probe captures the contractions of the perineal muscles in real time to allow the patient to do 5-minute exercises through fun games (jumping obstacles, jumping ...) sothat she remains motivated. The patient can follow her results as well as her progress in the application and unlock new universes according to the points obtained. Much of the effort of Fizimed's technical teams is focused on balancing a product, combining the quality and safety of a medical device, with a fun application to empower each woman. One goal: the simplicity of the product and the interface for home use.Beyond the product, the Fizimed team is committed to the fight against taboos related to urinary incontinence problems affecting one in ten women. She wants to "demystify" this topic so that every woman can find her adapted solution. An EMY community is being born on social networks in which the feminine hassles are put into images and discussed with humor, while talking about innovations that can simplify their daily lives.In summary, EMY by Fizimed is the connected and fun medical probe that allows women wishing to regain control of their perineum to do their home exercises. It was developed by a dynamic Alsatian start-up whose ambition is to remove taboos on a public health issue. | $4.3M / Mar 13, 2025 | |
Nova Carbon
|
Carbon fiber recycling | $1.1M / Seed / Feb 14, 2025 | |
| See all 107 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does UI Investissement invest in?
UI Investissement invests primarily in Manufacturing, Software and Health Care startups, most often at Private Equity and Seed stage. Most of the 107 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is UI Investissement's check size?
UI Investissement typically joins rounds of $1.5M–$5.8M at Seed, $3.2M–$33M at Series A and $3.2M–$49M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UI Investissement participates in.
How do I contact UI Investissement?
Public channels for UI Investissement include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UI Investissement?
The team at UI Investissement includes Hugues Béringer (Private Equity Associate), Michel Deprez (Managing Partner& Owner) and Stéphanie Pépineau (Associate Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
